Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | VEGFA | P15692 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PDE1A | P54750 | 1/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atizoram SCHEMBL14418236 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL7270902 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL450389 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL5083334 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL13016486 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL14473158 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL5963836 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL7270904 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL20883039 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL3416683 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | claimed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | claimed |
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | claimed |
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | NYCOMED GMBH (DE) | 2006-07-06 | — | — | US | claimed |
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | ALTANA PHARMA AG (DE) | 2006-04-13 | — | — | US | claimed |
| EP-1587512-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA Pharma AG (DE) | 2005-10-26 | — | — | EP | claimed |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | NYCOMED GMBH (DE) | 2005-05-26 | — | — | US | claimed |
| US-20050014762-A1 | Combination | NYCOMED GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| US-20040242597-A1 | Combination | NYCOMED GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| WO-2004062671-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA PHARMA AG (DE) | 2004-07-29 | — | — | WO | claimed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | claimed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| JP-3209322-A | — | — | None | — | — | JP | disclosed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| EP-0428313-A2 | Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders | PFIZER INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0247725-A2 | Calcium independent camp phosphodiestrerase inhibitor antidepressant | PFIZER INC. (US) | 1987-12-02 | — | — | EP | disclosed |
| WO-1987006576-A1 | CALCIUM INDEPENDENT CAMP PHOSPHODIESTERASE INHIBITOR ANTIDEPRESSANT | PFIZER INC. (US) | 1987-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | PDE4A, PDE12, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 7/4885 |
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE4A 1173/4885PDE4B 1204/4885PDE4C 1042/4885 |
| US-20050014762-A1 | Combination | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4C 8/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | PDE4A 959/4885PDE4B 803/4885PDE4C 1521/4885 |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | HRH4, PDE4A, PDE4B | PDE4A 2/4885PDE4B 3/4885PDE4C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.